Citation & Authors
Metabolism. 2026;185:156790.
ABSTRACT · RESEARCH SUMMARY
Research summary
This target trial emulation matched 564 pairs of liver transplant recipients with diabetes. GLP-1 users had lower risks of ischemic heart disease, heart failure, and death than SGLT2 users; the mortality HR was 0.622 (95% CI 0.433–0.894). The association with cirrhosis was only borderline significant and inconsistent across models. Infection, rejection, hepatic failure, and hospitalization did not differ significantly.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
Matching yielded 564 pairs. Compared with SGLT2 inhibitors, GLP-1 receptor agonists were associated with lower risks of heart failure (HR 0.502; 95% CI 0.388–0.650) and all-cause mortality (HR 0.622; 95% CI 0.433–0.894). Graft rejection did not differ significantly.
This study used observational data and cannot establish causality. Findings for cirrhosis risk were not fully consistent across sensitivity analyses and require confirmation in prospective studies.
